Aims: The purpose of this study was to determine prospectively whether p53 protein accumulation in biopsies of Barrett's metaplasia (BM) is a predictor of malignant progression, without relying on dysplasia grading. Methods and results: Sections of formalin-fixed paraffin-embedded tissue from the initial biopsies of 275 patients with BM, who had no high-grade dysplasia (HGD) or oesophageal adenocarcinoma (EAC), were stained for p53 by immunohistochemistry. The mean follow-up was 41 months. p53-positive biopsies were divided into four groups: scattered positive cells, multifocal scattered positive cells, aggregates of positive cells, and multifocal aggregates of positive cells. Kaplan-Meier analysis with the log-rank test was used to determine the rate of progression to HGD/ EAC. Of the 275 patients, 227 had initial biopsies that were completely negative for p53, and, of these, one (0.4%) progressed to HGD/EAC; none of 24 (0%) patients with scattered positive cells and none of four (0%) of patients with multifocal scattered positive cells progressed. In contrast, five of 16 (31.25%) patients with aggregates of positive cells and three of four (75%) of those with multifocal aggregates of positive cells progressed to HGD/EAC. Kaplan-Meier analysis with log-rank statistics showed the difference in progression rate between the five groups to be highly significant (P < 0.0001). Conclusions: We conclude that p53 protein accumulation, detected by immunohistochemistry in aggregates of cells, is a significant predictor of malignant progression in patients with BM.
Introduction
Barrett's metaplasia (BM) is a condition in which the normal squamous lining of the oesophagus is replaced by columnar epithelium containing intestinal-type goblet cells as a result of chronic gastroesophageal reflux disease. [1] [2] [3] BM is considered to be a premalignant condition, predisposing patients to an increased risk of oesophageal adenocarcinoma (EAC). Studies have shown that EACs detected in patients with BM undergoing surveillance tend to be of lower stage and to have a better outcome than EACs detected in patients not enrolled in surveillance programmes. [4] [5] [6] [7] [8] The frequency of endoscopic surveillance and the clinical management of patients with BM depend on the presence and grade of dysplasia in the oesophageal biopsy as determined by histopathological examination. [1] [2] [3] 9 Unfortunately, there is significant interobserver and intraobserver variation in the grading of dysplasia in BM, even among expert gastrointestinal pathologists, [10] [11] [12] [13] which may have a negative impact on the effectiveness and cost-effectiveness of endoscopic surveillance, clinical management, and the design of prevention studies. We previously proposed that p53 protein accumulation may be an objective marker of malignant progression in BM. [14] [15] [16] Our previous studies were retrospective, had limited sample sizes, and factored in dysplasia grading on initial biopsy. The purpose of this study was to determine prospectively whether p53 protein accumulation determined by immunohistochemical (IHC) staining of initial (index) oesophageal biopsies from patients with BM is a predictor of malignant progression, independently of dysplasia diagnosis.
Materials and methods

P A T I E N T S
The study protocol was first approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals in the year 2000. Patients were enrolled from both academic and community gastroenterology practices. Biopsies were performed at the following endoscopy suites in Texas Medical Center in Houston, TX: Houston Methodist Hospital, Medical Center Endoscopy, and Diagnostic Clinic of Houston (now part of Houston Methodist Hospital).
All patients gave consent before they were enrolled in the study. After exclusion of patients with highgrade dysplasia (HGD) or EAC on initial biopsy, the study population consisted of 275 patients with an endoscopically and histopathologically confirmed diagnosis of BM. Patient ages ranged from 21 to 91 years (mean, 62 years; median, 63 years), and the male/female ratio was 3.7:1. Follow-up ranged from 3 to 112 months (mean, 41 months; median, 43 months). All patients were prescribed high-dose proton pump inhibitors to be taken throughout the duration of the study; for those who could not afford this drug, or whose insurance did not cover it, free proton pump inhibitors were provided. None of the patients received ablation therapy while in the study. During the initial and follow-up endoscopies, four quadrant biopsies were taken from the Barrett's segment every 10-20 mm, and from any visible lesion, with regular biopsy forceps. Biopsies were sent to pathology for routine histology processing (formalin fixation and paraffin embedding). Index/initial biopsies are those obtained the first time that a patient consented to participate in this study. Histopathological evaluation was carried out by experienced gastrointestinal pathologists (M.Y. and G.Y.L.). Each biopsy was independently reviewed by two pathologists, and all disagreements were resolved by joint review. IHC staining was performed with a Dako automated autostainer (Dako, Carpenteria, CA, USA). The positive and negative controls were sections of formalinfixed paraffin-embedded cell lines HT29 and MCF7, respectively. Following steam heat antigen retrieval in 10 mM citrate buffer at pH 6.0 for 20 min followed by 10 min of cooling at room temperature, sections were incubated with a 1:2000 dilution of the antip53 monoclonal antibody BP-53-12 (BioGenex, Fremont, CA, USA) for 30 min at room temperature. The sections were washed in wash buffer, and the bound antibody was detected by the use of Dako's Envision Plus mouse peroxidase detection system with 3,3 0 -diaminobenzidine as chromogen, according to the manufacturer's instructions. The sections were finally counterstained with haematoxylin, mounted, and coverslipped.
The initial batches of slides with p53 immunostaining were jointly scored by two pathologists (M.Y. and K.B.), however, because of the excellent agreement, p53 immunostaining on the remaining slides was evaluated and scored by one author (K.B.), who was blinded to patient information, clinical and endoscopic data, and grade of dysplasia. Positive staining (protein accumulation) was defined as nuclear staining with the same staining intensity (3+) as the positive control cell line HT29. p53-positive biopsies were further subdivided into four groups, as follows.
P: scattered positive cells, when there is a minimum of one cell with nuclear p53 accumulation (3+) but no aggregates of positive cells. PM: multifocal scattered positive cells, when there are scattered p53-positive cells as defined in 'P' above, but in biopsies from more than one location in the oesophagus obtained in the same endoscopy session (such as in biopsies from 320 mm and in biopsies from 300 mm).
PA: aggregates of positive cells, when there is at least one gland with at least 50% of the nuclei positive for p53 protein accumulation (3+).
PAM: multifocal aggregates of positive cells, where there is at least one gland with at least 50% of the nuclei positive for p53 protein accumulation (3+) in biopsies from more than one location in the oesophagus obtained in the same endoscopy session.
S T A T I S T I C A L A N A L Y S I S
Kaplan-Meier analysis with the log-rank test was used to determine the rate of progression in the different groups according to the p53 status in the initial biopsies, with progression to either HGD or EAC considered to be an end result (failure). Fisher's exact test was used for all other analyses. Statistical analysis was performed with PRISM version 6.0 for Macintosh (GraphPad Software, San Diego, CA, USA) with twotailed P-tests and 95% confidence intervals.
Results
Two hundred and seventy-five patients with at least one follow-up biopsy participated in the study. The median age of the patients was 63 years (range, 21-91 years), and the male/female ratio was 3.7:1.
Examples of p53 immunostaining are shown in Figure 1 . Of the 275 patients enrolled in this large prospective study, 227 had initial (index) biopsies that were completely negative for p53, and, of these, only one (0.4%) progressed to HGD/EAC. None of 24 (0%) patients with P and none of four (0%) patients with PM progressed. In contrast, five of 16 (31.25%) patients with PA and three of four (75%) patients with PAM on initial biopsy progressed to HGD/EAC. Kaplan-Meier analysis showed a significant rate of progression to HGD/EAC in patients with BM whose index biopsies showed either a PA or a PAM pattern of p53 accumulation as compared with patients in the other patient groups (P < 0.0001; Figure 2A) .
Next, we combined the PA and PAM groups as positive for p53 protein accumulation defined as any biopsy with at least one crypt showing ≥50% of the nuclei with strong p53 staining, and all other groups (N, P, and PM) as negative for p53 protein accumulation. There were 20 cases with p53 protein overexpression in initial biopsies, of which eight (40%) progressed to HGD/EAC. This is in sharp contrast to the 255 cases with initial biopsies negative for p53 protein accumulation, of which only one (0.3%) progressed to HGD/EAC (P < 0.0001; Figure 2B ). Of the combined p53-positive initial (index) biopsies (PA and PAM), five were negative for dysplasia (ND), five were indefinite for dysplasia (IND) and 10 were low-grade dysplasia (LGD) by histopathological examination. Of the combined p53-negative initial biopsies, 187 were ND, 49 were IND, and 19 were LGD.
Discussion
The incidence of EAC in the USA has been rising since the early 1970s, and although the most dramatic increase has occurred in white males, increases in the incidence in Hispanics and in white females appear to be occurring at a similar rate, but to a much smaller extent. 17 EAC is associated with very poor survival. 17 The precursor lesion for EAC is BM. It has been estimated that 5.6% of the US population have BM. 18 In order to decrease the mortality resulting from EAC, patients with BM are enrolled in surveillance programmes, in which oesophageal endoscopy and biopsy are performed at regular intervals depending on several factors, the most important of which is the grade of dysplasia found on biopsy. 3, 9 Unfortunately, the cornerstone of surveillance programmes, dysplasia grading, suffers from significant variation in reproducibility, even among experts in gastrointestinal pathology. Pathologists in general practice were found to have even more problems with dysplasia grading in BM, 19, 20 and it has been recommended that the grade of dysplasia be confirmed by an expert pathologist. 3 We previously proposed that p53 protein accumulation in biopsies from patients with BM, detected by IHC staining, is a predictor of malignant progression. [14] [15] [16] Although initial studies of p53 expression in BM focused largely on correlation with the grade of dysplasia, [21] [22] [23] [24] [25] [26] [27] [28] subsequent studies confirmed that p53 protein accumulation in BM correlates with malignant progression. [29] [30] [31] [32] [33] However, these studies, including our own, were retrospective in nature, and were all, in some way, dependent on dysplasia grading.
In this prospective study, our results clearly show that p53 accumulation is a significant predictor of cancer risk in biopsies with BM negative for HGD or EAC. Importantly, malignant progression is predicted without the need to first stratify the biopsies based on dysplasia. The initial biopsies entered into this study had 54 cases of IND and 29 of LGD, for a combined LGD/IND of 83. Traditionally, this is considered to be the high-risk group that is most likely to benefit from surveillance and/or prevention measures. In contrast, p53 accumulation, according to our criteria, narrows down this group of at-risk patients to just 20 patients. Scattered p53-positive cells probably Two recent studies, including a large prospective study, confirmed the predictive value of p53 IHC staining in biopsies of patients with BM. The authors of these studies defined a pattern of p53 overexpression, which is generally similar to ours, as strong nuclear staining except in single nuclei. 34, 35 The scoring of p53 overexpression was also found to be more reproducible and a better predictor of progression to HGD/ECA than dysplasia grading on haematoxylin and eosin (H&E) slides. 34, 35 Murray et al. included 'diffuse staining' together with strong staining in one category as positive p53 staining, and concluded that p53 IHC staining has low sensitivity as a biomarker of malignant progression in BM. 36 Therefore, it is important to restrict the definition of positive staining to strong nuclear staining that is present in more than just scattered nuclei.
Up to only a few years ago, all studies examining p53 expression in BM by using IHC staining focused on p53 protein overexpression/accumulation as the only p53 abnormality, and that was largely considered to represent p53 gene mutation that led to decreased degradation/stabilization and accumulation of the p53 protein in the nucleus. Recently, a second pattern of abnormal p53 expression has been described 34 and called the 'absent pattern'. It was found in a smaller number of cases, and was defined as an absence of p53 staining in a focus in an area of interest as compared with the low-level staining in non-dysplastic glandular epithelium which is referred to as normal expression. 34 We did not detect 'normal expression' in our cases, so detection of the 'absent' pattern in our series was not possible. We titrated down our p53 antibody with two formalin-fixed paraffin-embedded cell lines, one of which is known to harbour a p53 mutation (and to overexpress p53), and the other of which has wild-type p53. We optimized our staining conditions to produce strong nuclear staining in the cell line with p53 mutation and no staining in the cell line with wild-type p53, and this may have been the cause of our inability to detect wild-type p53 in our cases. However, the absent pattern seems to be largely detected in HGD and EAC, 34 and, as we excluded such cases from our cohort, we would not expect to see the absent pattern in our initial biopsies, even if we used higher antibody concentration. Furthermore, because of its detection largely in cases with HGD/EAC, it is likely that an absent p53 staining pattern is a late event in neoplastic progression in BM, and may not be valuable as a predictive marker.
The number of patients in our study who progressed to HGD/EAC was lower than expected. This is probably because all participating patients were taking high-dose proton pump inhibitors. [37] [38] [39] [40] [41] [42] Because our findings largely confirm those of another large prospective study, 34 and p53 IHC scoring was found to be largely reproducible, 34, 35 future research should focus on whether p53 protein accumulation could replace dysplasia grading, which may lead to increased cost-effectiveness of surveillance and prevention programmes for patients with BM.
